skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Cenicriviroc  Audio icon

Other Names: cenicriviroc mesylate, CVC, TAK-652, TBR-652
Drug Class: Entry and Fusion Inhibitors
Molecular Formula: C41 H52 N4 O4 S
Registry Number: 497223-25-3 (CAS)
Chemical Name: (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide
Chemical Class: Benzazepines
Company: Takeda; Tobira Therapeutics
Phase of Development: Phase IIb
Chemical Image:
Click image to enlarge
cenicriviroc
cenicriviroc
Molecular Weight: 696.9518
(Compound details obtained from ChemIDplus Advanced1 and NIAID Therapeutics Database2)

What is an investigational drug?

An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.

What is cenicriviroc?

Cenicriviroc is an investigational drug that is being studied for the treatment of HIV infection.

Cenicriviroc belongs to a class (group) of HIV drugs called entry and fusion inhibitors.2 Entry and fusion inhibitors block HIV from getting into and infecting certain cells of the immune system. This prevents HIV from multiplying and can reduce the amount of HIV in the body.

Cenicriviroc works by attaching to one of two proteins on the surface of the immune cells. These proteins are called the CCR5 and CXCR4 coreceptors. Cenicriviroc attaches to the CCR5 coreceptor. When cenicriviroc attaches to the CCR5 coreceptor, certain strains of HIV—called R5-tropic virus—cannot attach to, enter, or infect the cell.3

Cenicriviroc also appears to block another receptor known as CCR2. The CCR2 receptor is associated with inflammatory diseases. The potential benefits of blocking the CCR2 receptor in people with HIV are being studied.4,5 

How are clinical trials of investigational drugs conducted?

Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.6

Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.6

In most cases, an investigational drug must be proven safe and effective in a Phase III clinical trial to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.6 


In what phase of testing is cenicriviroc?

Cenicriviroc has been studied in a Phase IIb clinical trial.2,7

What have recent studies shown about cenicriviroc?

In a 48-week Phase IIb study (known as Study 202), two different strengths of cenicriviroc taken orally and once daily were compared to the HIV medicine efavirenz (an FDA-approved non-nucleoside reverse transcriptase inhibitor [NNRTI]; brand name: Sustiva). Participants were HIV-infected adults with R5-tropic HIV (virus that uses CCR5 as a coreceptor). Participants had never taken HIV medicines before entering the study (called treatment-naive).7,8
 
During the study, participants also received the FDA-approved medicine Truvada (a combination tablet that contains the HIV medicines emtricitabine [brand name: Emtriva] and tenofovir disoproxil fumarate [brand name: Viread]) as part of their background regimen. (A background regimen is a combination of drugs that are not being studied as the investigational drug[s] in the clinical trial, but are being given to help control a participant’s HIV infection.) Also, depending on which treatment group participants were assigned to, they took placebos of some of the medicines. (A placebo is an inactive drug that is identical in appearance to the active drug.)7,8
  
In this study, cenicriviroc was as effective as efavirenz at reducing HIV viral load (the amount of HIV in a blood sample). Cenicriviroc also appeared to block the CCR2 receptor and decrease levels of a certain marker of inflammation called soluble CD14. (Soluble CD14 may be associated with an increased risk of death and other disease states in HIV-infected individuals.) In terms of safety, fewer cenicriviroc participants than efavirenz participants experienced a severe side effect or dropped out of the study because of a side effect.8-11

The company developing cenicriviroc is planning Phase III clinical trials to investigate a fixed-dose combination (FDC) tablet containing cenicriviroc plus the FDA-approved medicine lamivudine (brand name: Epivir).12

In addition, a Phase II study will be looking at the effectiveness and safety of cenicriviroc as a treatment for mild to moderate HIV-associated neurocognitive disorder (HAND).13 (HAND ranges from mild problems with memory, language, and reasoning to the more severe HIV-associated dementia [HAD].)

 

What side effects might cenicriviroc cause?

In Study 202 discussed under the previous question, side effects related to treatment occurred in participants across all study groups, but occurred in a smaller percentage of cenicriviroc-treated participants than efavirenz-treated participants. Total and LDL cholesterol levels decreased in participants receiving cenicriviroc, but increased in participants receiving efavirenz.8,9

Because cenicriviroc is still being studied, information on possible side effects of the drug is not complete. As testing of cenicriviroc continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying cenicriviroc?

More information about cenicriviroc-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

I am interested in participating in a clinical trial of cenicriviroc. How can I find more information about participating in a clinical trial?

Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.6 

Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

References

  1. United States National Library of Medicine. ChemIDplus Advanced. Available at: http://chem.sis.nlm.nih.gov/chemidplus/rn/497223-25-3. Last accessed on September 3, 2014.
  2. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Available at: http://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Last accessed on September 3, 2014.
  3. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother. 2006 Apr;57(4):619-27. Available at: http://jac.oxfordjournals.org/content/57/4/619.long. Last accessed on September 3, 2014.
  4. Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 2011 Jun;55(6):2768-74. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101382/. Last accessed on September 3, 2014.
  5. Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs. 2010 Aug;11(8):940-50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20721836. Last accessed on September 3, 2014.
  6. National Institutes of Health (NIH). NIH Clinical Research Trials and You. Available at: http://nih.gov/health/clinicaltrials/index.htm. Last accessed on September 3, 2014.
  7. Tobira Therapeutics, Inc. A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 18, 2011. NLM Identifier: NCT01338883. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01338883. Last accessed on September 3, 2014.
  8. Feinberg J, Thompson M, Cade J, et al. Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus (Study 652-2-202; NCT01338883). 14th European AIDS Conference; October 16-19, 2013; Brussels, Belgium. Levin: Conference Reports for National AIDS Treatment Advocacy Project (NATAP); 2013. Available at: http://www.natap.org/2013/EACS/EACS_10.htm. Last accessed on September 3, 2014.
  9. Feinberg J, Thompson M, Cade J, et al. Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-naïve HIV-1-infected Adults with CCR5-Tropic Virus. Abstract presented at: 14th European AIDS Conference; October 16-19, 2013; Brussels, Belgium. Abstract PS4/1. Available at: http://www.professionalabstracts.com/eacs2013/planner/index.php?go=abstract&action=abstract_iplanner&print=0&lprID=142&highlight=cenicriviroc&PSID=AOLYUNDFJHCSEFPDLAAC. Last accessed on September 3, 2014.
  10. Shepp DH. Inflammation and HIV at CROI 2013: Focus on the Monocyte/Macrophage Axis and Innate Immunity. Conference Reports for National AIDS Treatment Advocacy Project (NATAP): 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2013; Atlanta, GA. Available at: http://www.natap.org/2013/CROI/croi_66.htm. Last accessed on September 3, 2014.
  11. Anzinger JJ, Butterfield TR, Angelovich TA, Crowe SM, Palmer CS. Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART. J Immunol Res. 2014;2014:569819. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082935/. Last accessed on September 3, 2014.
  12. Tobira Therapeutics: News, dated October 17, 2013. Tobira Therapeutics Presents Positive 48-Week Data from Phase 2b Trial of Cenicriviroc in Treatment-Navie HIV Infection at the 14th European AIDS Conference. Available at: http://www.tobiratherapeutics.com/file.cfm/7/docs/pr_10_17_13.pdf. Last accessed on September 3, 2014.
  13. University of Hawaii. Randomized, Placebo-Controlled, Double-Blind, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 4, 2013. NLM Identifier: NCT02128828. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02128828. Last accessed on September 3, 2014.
 


Last Reviewed: September 3, 2014

Last Updated: September 3, 2014


Back to Top